{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T20:59:21Z","timestamp":1761512361668},"reference-count":18,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2006,7,20]],"date-time":"2006-07-20T00:00:00Z","timestamp":1153353600000},"content-version":"vor","delay-in-days":8601,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[1983,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Orchiectomy or chronic administration of the gonadotropin releasing hormone agonistic analogue D, Ser (TBU)<jats:sup>6<\/jats:sup>, des Gly\u2010NH<jats:sub>2<\/jats:sub><jats:sup>10<\/jats:sup> ethylamide (HOE 766) were employed as therapeutic maneuvers in 25 patients with advanced prostatic carcinoma. HOE 766 administration effectively suppressed plasma testosterone to castrate levels that persisted for as long as treatment continued. Surgical and medical castration resulted in a significant decrease in prostatic size; this became evident earlier for surgically than medically treated patients (P &lt;.05), but no difference existed after the third month of treatment. Symptoms and signs of prostatism improved in practically all the patients. Among patients with stage D<jats:sub>2<\/jats:sub> disease, there was an improvement in five as far as bone radiological assessment was concerned. Alkaline phosphatase levels did not show appreciable changes in patients showing objective stable disease or partial response according to National Prostatic Cancer Project criteria. Radioimmunoassayable prostatic acid phosphatase levels became normal in two of two stage C, five of five stage D<jats:sub>1<\/jats:sub>, and eight of seventeen patients with stage D<jats:sub>2<\/jats:sub> disease, a rise in prostatic acid phosphatase (PAP), in alkaline phosphatase, and deterioration in bone radiology were associated with clinical evidence of relapse; this occured despite persistently low levels of plasma testosterone. Serum thyroxine, cortisol, and prolactin levels remained unchanged following orchiectomy or chronic administration of HOE 766. Practically all patients complained of hot flashes and experienced a decrease in libido and potency, but none developed gynecomastia or thromboembolic episodes. The data indicate that HOE 766 can be used safely as an alternative to castration or estrogens for the treatment of patients with androgen\u2010dependent prostatic cancer.<\/jats:p>","DOI":"10.1002\/pros.2990040604","type":"journal-article","created":{"date-parts":[[2007,2,21]],"date-time":"2007-02-21T00:10:16Z","timestamp":1172016616000},"page":"569-577","source":"Crossref","is-referenced-by-count":24,"title":["Gonadotropin\u2010releasing hormone agonistic analogues in the treatment of advanced prostatic carcinoma"],"prefix":"10.1002","volume":"4","author":[{"given":"M.","family":"Koutsilieris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Tolis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,20]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"293","article-title":"Studies on Prostate Cancer: The effect of castration, of estrogen, and of androgen injection of serum phosphatase in metastatic carcinoma of the prostate","volume":"1","author":"Huggins C","year":"1941","journal-title":"Cancer Res"},{"key":"e_1_2_1_3_2","first-page":"1011","article-title":"Treatment and survival of patients with cancer of the prostate","volume":"124","author":"Veterans Administration Co\u2010op Urological Research Group","year":"1967","journal-title":"Surg Gynecol Obstet"},{"key":"e_1_2_1_4_2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0094-0143(21)00151-8","article-title":"The questionable use of hormone therapy in advanced carcinoma of the prostate","volume":"713","author":"Murphy G. P.","year":"1980","journal-title":"Urol Clin North Am"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.1980.45.s7.1929"},{"key":"e_1_2_1_6_2","first-page":"349","article-title":"Methods for the determination of androgen receptor content in human prostatic tissue","volume":"18","author":"Trachtenberg J","year":"1981","journal-title":"J Urol"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.3109\/01485018008986992"},{"key":"e_1_2_1_8_2","first-page":"344","article-title":"Endocrine manipulation in cancer of the prostate","volume":"36","author":"Falcone T","year":"1983","journal-title":"Biomedicine."},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.79.5.1658"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(82)92279-6"},{"key":"e_1_2_1_11_2","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S0015-0282(16)46107-8","article-title":"Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone\u2010releasing hormone (LHRH) agonist in adult men","volume":"37","author":"Faure N","year":"1982","journal-title":"Fertil Steril"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-4731(83)90045-6"},{"key":"e_1_2_1_13_2","first-page":"56","article-title":"Extrapituitary inhibition of testicular function by luteinizing hormone\u2010releasing hormone","volume":"281","author":"Hsu\u0117h ATW","journal-title":"Nature"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110320"},{"key":"e_1_2_1_15_2","first-page":"1","article-title":"Application of LHRH and its superactive analogues in reproductive biology","volume":"15","author":"Tolis G","year":"1981","journal-title":"Front Horm Res"},{"key":"e_1_2_1_16_2","first-page":"271","article-title":"Luteolytic effect of a luteinizing hormone\u2010 releasing hormone (LHRH) analogue (D\u2010Tryp6\u2010LHRH) in the non\u2010human primate: Its mechanism of action","volume":"36","author":"Asch R","year":"1982","journal-title":"Fertil Steril"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)53165-1"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810601)47:11<2585::AID-CNCR2820471113>3.0.CO;2-U"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.146.2.6294738"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.2990040604","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.2990040604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T08:05:21Z","timestamp":1697789121000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.2990040604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1983,1]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1983,1]]}},"alternative-id":["10.1002\/pros.2990040604"],"URL":"https:\/\/doi.org\/10.1002\/pros.2990040604","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[1983,1]]}}}